Furthermore, survival analysis revealed that T‐ALL patients with higher KLF3 expression levels had longer overall survival (OS) and better prognosis, whereas T‐ALL patients with lower TCF3 expression levels showed shorter OS and poorer prognosis (Figure 3F). The gene discussed is KLF3; the disease is acute lymphoblastic leukemia.